Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q64052870)
Watch
English
Pazopanib in advanced soft tissue sarcomas
scientific article published on 17 May 2019
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
6522548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31123606%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 April 2020
review article
1 reference
stated in
Europe PubMed Central
title
Pazopanib in advanced soft tissue sarcomas
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
6522548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31123606%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 April 2020
author
Robin L Jones
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
6522548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31123606%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 April 2020
Paul H. Huang
series ordinal
3
1 reference
stated in
Europe PubMed Central
PMC publication ID
6522548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31123606%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 April 2020
author name string
Alex T J Lee
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
6522548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31123606%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 April 2020
publication date
17 May 2019
1 reference
stated in
Europe PubMed Central
PMC publication ID
6522548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31123606%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 April 2020
published in
Signal Transduction and Targeted Therapy
1 reference
stated in
Europe PubMed Central
PMC publication ID
6522548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31123606%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 April 2020
volume
4
1 reference
stated in
Europe PubMed Central
PMC publication ID
6522548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31123606%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 April 2020
issue
1
0 references
page(s)
16
1 reference
stated in
Europe PubMed Central
PMC publication ID
6522548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31123606%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 April 2020
cites work
Activity-based kinase profiling of approved tyrosine kinase inhibitors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
New affinity probe targeting VEGF receptors for kinase inhibitor selectivity profiling by chemical proteomics.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phosphoproteomics in translational research: a sarcoma perspective.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in Canada
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cost-effectiveness of pazopanib in advanced soft tissue sarcoma in the United kingdom
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pazopanib inhibits the activation of PDGFRβ-expressing astrocytes in the brain metastatic microenvironment of breast cancer cells
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I trial of pazopanib in patients with advanced cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pazopanib versus sunitinib in metastatic renal-cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization f
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interethnic variation of drug metabolism
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ethnic differences in drug metabolism and toxicity from chemotherapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study().
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical and Molecular Spectrum of Liposarcoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
We should desist using RECIST, at least in GIST.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Early metabolic response as predictor for treatment outcome of pazopanib in patients with metastatic soft tissue sarcomas (the PREDICT study)
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Immunity and HER2-positive disease: never stop questioning.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Proteomic approach toward determining the molecular background of pazopanib resistance in synovial sarcoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinically Relevant Molecular Subtypes in Leiomyosarcoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FS41392-019-0049-6
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
TP53 mutational status is predictive of pazopanib response in advanced sarcomas
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/31123606
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1038/S41392-019-0049-6
1 reference
stated in
Europe PubMed Central
PMC publication ID
6522548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31123606%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 April 2020
PMC publication ID
6522548
1 reference
stated in
Europe PubMed Central
PMC publication ID
6522548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31123606%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 April 2020
PubMed publication ID
31123606
1 reference
stated in
Europe PubMed Central
PMC publication ID
6522548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31123606%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 April 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
